Thursday, 18 Jan 2018

You are here

Biologic Use in Adult-Onset Still's Disease

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.

Currently there are no drugs (including biologics) specifically approved for use in AOSD, yet there are several that approved for use in SoJIA - indicated for use in active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older:  

Approved Biologics for SoJIA

  • Ilaris (canakinumab) 
  • Actemra (tocilizumab) 

Biologics Not Approved (but occassionally used)

  • Arcalyst (rilonacept) is an interleukin-1 blocker 
  • Kineret (anakinra): is an IL-1 receptor antagonist

Biologics Under Study (according to clinicaltrials.gov)

  • Ilaris (canakinumab) - under study for AOSD
  • Kineret (anakinra): under study for AOSD and SoJIA

A recent systematic review of the literature identified those biologic drugs that have been studied in AOSD. The meta-analysis included 19 observational studies and showed overall rate of clinical response of 0.85 (95% CI: 0.77-0.91, p < 0.0001) and an overall rate of complete remission of 0.66 (95% CI: 0.54-0.77, p = 0.01). These studies were hampered by a high rate of heterogeneity (Q=59.82 with df=19.0,p<0.0001,I2=68.23%).

Most of these results are driven by the success of IL-1 or IL-6 inhibition in controlling the systemic features of Still's disease - including fever, rash, hepatosplenomegaly, lymphadenopathy, arthritis, serositis and aggressively inflammatory indices.

TNF inhibitors are NOT effective enough to warrant use in those with active inflammatory systemic disease, but may be considered in those whose disease has settled into a dominant rheumatoid-like chronic, polyarthritis.

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source: https://buff.ly/2zXyY2X)

BMS Featured Presentations from ACR 2017

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Biosimilars Projected to Yield $54 Billion in Savings

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.